Novartis
NVS
1,181 hedge funds and large institutions have $15.2B invested in Novartis in 2023 Q1 according to their latest regulatory filings, with 97 funds opening new positions, 352 increasing their positions, 499 reducing their positions, and 73 closing their positions.
150% more call options, than puts
Call options by funds: $564M | Put options by funds: $226M
33% more first-time investments, than exits
New positions opened: 97 | Existing positions closed: 73
8% more funds holding in top 10
Funds holding in top 10: 13 → 14 (+1)
0.42% more ownership
Funds ownership: 7.12% → 7.54% (+0.42%)
0% less funds holding
Funds holding: 1,183 → 1,181 (-2)
1% less capital invested
Capital invested by funds: $15.3B → $15.2B (-$109M)
29% less repeat investments, than reductions
Existing positions increased: 352 | Existing positions reduced: 499
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Envestnet Asset Management
Chicago,
Illinois
|
+$619M |
| 2 |
Goldman Sachs
New York
|
+$242M |
| 3 |
Bank of America
Charlotte,
North Carolina
|
+$108M |
| 4 |
Point72 Asset Management
Stamford,
Connecticut
|
+$96.6M |
| 5 |
Millennium Management
New York
|
+$81.6M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Loomis, Sayles & Company
Boston,
Massachusetts
|
-$379M |
| 2 |
Arrowstreet Capital
Boston,
Massachusetts
|
-$345M |
| 3 |
Two Sigma Advisers
New York
|
-$93.8M |
| 4 |
Primecap Management
Pasadena,
California
|
-$67.1M |
| 5 |
MSE
MUFG Securities EMEA
London,
United Kingdom
|
-$55.1M |
NVS Hedge Fund Activity: Q1 2023 in Review
1,181 of the 6,276 institutional investors tracked by Wall St. Rank reported a position in Novartis (NVS) for Q1 2023, worth a combined $15.2B — down 0.71% from $15.3B a quarter earlier.
Buyers outnumbered sellers: 97 funds opened new NVS positions and 73 closed out — a net gain of 24 holders — while 352 added to existing stakes and 499 trimmed.
The largest buyer was Envestnet Asset Management, adding an estimated $619M. The largest seller was Loomis, Sayles & Company, cutting an estimated $379M.
- 1,181 institutional investors held Novartis (NVS) as of Q1 2023, down from 1,183 in Q4 2022.
- Funds reported $15.2B of Novartis stock for Q1 2023, down 0.71% quarter-over-quarter.
- 97 funds opened new Novartis positions in Q1 2023 and 73 closed out, a net change of +24 holders.
- The largest Novartis buyer in Q1 2023 was Envestnet Asset Management, an estimated $619M added.
- The largest Novartis seller in Q1 2023 was Loomis, Sayles & Company, an estimated $379M sold.
Based on aggregated 13F filings for Q1 2023.